SEARCH

SEARCH BY CITATION

References

  • 1
    Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994; 105:897904.
  • 2
    Ferrari R, Ceconi C, Curello S, et al. The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J. 1998;19(suppl F):F45F51.
  • 3
    Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:10501053.
  • 4
    Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr Opin Cardiol. 1999;14:211216.
  • 5
    Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236241.
  • 6
    Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704711.
  • 7
    Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280287.
  • 8
    Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:14871493.
  • 9
    Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526534.
  • 10
    Adams V, Jiang H, Jiangtao Y, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959965.
  • 11
    Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantely acute cachexia. J Clin Invest. 1990;86:20142024.
  • 12
    McMurray J, Abdullah I, Dargie HJ, et al. Increased concentrations of tumour necrosis factor in “cachectic” patients with severe chronic heart failure. Br Heart J. 1991;66:356358.
  • 13
    Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:28542865.
  • 14
    Bolger AP, Anker SD. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs. 2000;60:12451257.
  • 15
    Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:14791486.
  • 16
    Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683693.
  • 17
    Dibbs Z, Thornby J, White B, et al. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol. 1999;33:19351942.
  • 18
    Leyva F, Anker SD, Egerer K, et al. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J. 1998;19:15471551.
  • 19
    Murdoch DR, Rooney E, Dargie HJ, et al. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart. 1999;82:352356.
  • 20
    Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997;18:259269.
  • 21
    Anker SD, Volterrani M, Egerer KR, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM. 1998;91:199203.
  • 22
    Vanderheyden M, Kersschot E, Paulus WJ. Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. Eur Heart J. 1998;19:747752.
  • 23
    Francis SE, Holden H, Holt CM, et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30:215223.
  • 24
    Gulick T, Chung MK, Pieper SJ, et al. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA. 1989;86:67536757.
  • 25
    Munger MA, Johnson B, Amber IJ, et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;77:723727.
  • 26
    Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376382.
  • 27
    Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:12011206.
  • 28
    Carlstedt F, Lind L, Lindahl B. Proinflammatory cytokines measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med. 1997;242:361365.
  • 29
    Roig E, Orus J, Pare C, et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;82:688690.
  • 30
    Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391398.
  • 31
    Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 1999;83:612615, A10.
  • 32
    Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000; 102:30603067.
  • 33
    Orus J, Roig E, Perez-Villa F, et al. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant. 2000; 19:419425.
  • 34
    Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999;22:811813.
  • 35
    Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998;19:18141822.
  • 36
    Sharma R, Rauchhaus M, Ponikowski PP, et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2000;36:523528.
  • 37
    Kapadia SR, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187195.
  • 38
    Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 1997;79:14261430.
  • 39
    Matsumori A, Shioi T, Yamada T, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994;89:955958.
  • 40
    Vonhof S, Brost B, Stille-Siegener M, et al. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. Int J Cardiol. 1998;63:237244.
  • 41
    Zhao SP, Xu TD. Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure. Int J Cardiol. 1999;71:257261.
  • 42
    Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:18381842.
  • 43
    Kapadia S, Lee J, Torre-Amione G, et al. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96:10421052.
  • 44
    Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761765.
  • 45
    Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail. 1999;1:309312.
  • 46
    Francis GS. Neurohormonal mechanisms involved in congestive heart failure. Am J Cardiol. 1985;55(suppl A):15A21A.
  • 47
    Davis R, Ribner HS, Keung E, et al. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med. 1979;301:117121.
  • 48
    Omland T, Aakvaag A, Bonarjee V, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:19631969.
  • 49
    Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248254.
  • 50
    Cohn JN, Levine B, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819823.
  • 51
    Gottlieb S, Kukin M, Ahern D, et al. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:15341539.
  • 52
    Anker SD. Catecholamine levels and treatment in chronic heart failure. Eur Heart J. 1998;19:F56F61.
  • 53
    Poehlman ET, Scheffers J, Gottlieb SS, et al. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med. 1994;121:860862.
  • 54
    Swan JW, Walton C, Godsland IF, et al. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:15281532.
  • 55
    Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527532.
  • 56
    Paolisso G, Tagliamonte MR, Rizzo MR, et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol. 1999;83:13381344.
  • 57
    Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43:12711278.
  • 58
    Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998;32:393397.
  • 59
    Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:12331237.
  • 60
    Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998;19:17041711.
  • 61
    Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997;30:9971001.
  • 62
    Grange JM. The endocrine system and the immune response: prospects for novel therapeutic approaches. Q J Med. 1996;89:323325.
  • 63
    Sigurdsson A, Swedberg K, Ullman B. Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure. Eur Heart J. 1994;15:247254.
  • 64
    Van Veldhuisen DJ, Genth-Zotz S, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998;32: 18111818.
  • 65
    Liu L, Zhao SP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol. 1999;69:7782.
  • 66
    Gullestad L, Aukrust P, Ueland T, et al. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34:20612067.
  • 67
    Corbalan R, Acevedo M, Godoy I, et al. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail. 1998;4:115119.
  • 68
    Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000;35:714721.
  • 69
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709717.
  • 70
    Kinugawa T, Ogino K, Kato M, et al. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. Gen Pharmacol. 1998;31:9399.
  • 71
    Walter M, Liebens I, Goethals H, et al. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol. 1988;25:323329.
  • 72
    Renard M, Walter M, Liebens I, et al. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest. 1988;93:11591164.
  • 73
    Hagemeijer F, Brand HJ, Roth W. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol. 1989;14:302310.
  • 74
    Sasayama S, Matsumori A, Matoba Y, et al. Immunomodulation: a new horizon for medical treatment of heart failure. J Card Fail. 1996;2:S287S294.
  • 75
    Matsumori A, Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy—lessons from animal experiments. Eur Heart J. 1995;16:140143.
  • 76
    Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol. 1999;33:14001407.
  • 77
    Matsumori A, Ono K, Nishio R, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation. 1997;96:15011506.
  • 78
    Nishio R, Matsumori A, Shioi T, et al. Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. J Am Coll Cardiol. 1998;32:808815.
  • 79
    Freeman L, Rush J, Kehayias J, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med. 1998;12:440448.
  • 80
    Bozkurt B, Kribbs S, Clubb F Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:13821391.
  • 81
    Kapadia S, Torre-Amione G, Yokoyama T, et al. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol. 1995;268:H517H525.
  • 82
    Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220225.